Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

AMARIN CORP PLC\UK (AMRN)

$13.55 -0.37% NASDAQ: AMRN · 15-min delayed
  • DUBLIN 2,
  • Public · NASDAQ: AMRN
  • 80 employees
$292.1MMarket cap
$213.6MRevenue · FY2025
-$38.8MNet income
80Employees
AMRNNASDAQ
1993IPO

About AMARIN CORP PLC\UK

Amarin Corp PLC is a pharmaceutical company. The company is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa. The company focuses on treatments to stop cardiovascular disease causing death, by providing patients, doctors and investors with reliable cardiovascular treatment options. Geographically, the company derives maximum revenue from United States.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2025
$213.6M
Net income
-$38.8M
Total assets
$670.8M
Market cap
$292.1M
Gross margin
56.6%
Operating margin
-23.5%
Net margin
-18.2%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$213.6M
Cost of revenue
$92.8M
Gross profit
$120.9M
Operating expenses
$171.0M
Operating income
-$50.2M
Income tax
$2.8M
Net income
-$38.8M
EPS (basic)
$-0.09
EPS (diluted)
$-0.09

Balance sheet

Total assets
$670.8M
Current assets
$649.9M
Total liabilities
$211.5M
Current liabilities
$194.5M
Shareholders’ equity
$459.3M

Cash flow

Operating cash flow
$6.7M
Investing cash flow
$8.8M
Financing cash flow
-$2.0M
Net cash flow
$13.5M

Statements via Polygon.io (SEC filings)

NASDAQ: AMRN
$13.55 -0.37%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$12.54 $20.25

52-week range

Market cap
$292.1M
EPS (diluted)
$-0.09
Shares outstanding
21.6M
Open
Day range
Prev close
Volume
IPO date
Apr 1, 1993

Amarin Corp Plc\uk (AMRN) Stock Price

  • Reported a net loss of $38.8M in FY2025.
  • Revenue declined 63% from FY2021 to FY2025.
  • Gross margin of 56.6%, net margin -18.2%.
  • Trading 33% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review AMARIN CORP PLC\UK.

Write a review
Newsroom

News about AMARIN CORP PLC\UK

News & sentiment via Polygon.io

FAQ

Amarin Corp Plc\uk: frequently asked questions

Is Amarin Corp Plc\uk an American company?

Amarin Corp Plc\uk is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Is Amarin Corp Plc\uk publicly traded?

Yes — Amarin Corp Plc\uk is a publicly traded company. Its stock trades under the ticker symbol AMRN on the NASDAQ.

What does Amarin Corp Plc\uk do?

Amarin Corp Plc\uk is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →